Pfizer CEO Albert Bourla on Monday claimed the pharmaceutical big will be capable of present Seagen’s most cancers remedy to the world at a scale that has not been seen earlier than, Eagen’s with its $43 billion acquisition.
“We can add value to what Seagen is bringing,” Bourla mentioned in a CNBC interview. “It’s more or less a situation like when mRNA was in our hands. “With our scale, with our capabilities, this is the same here,” the CEO added additional.
Seagen is a pioneer within the…
